Most cited papers from Ambrx (United States)

Ambrx (United States)

What are the most cited papers from Ambrx (United States)?

The most cited paper from Ambrx (United States) is "Synthesis of site-specific antibody-drug conjugates using unnatural amino acids" (Jun Y. Axup et al., 2012), with 594 citations. Next come "A general approach to site-specific antibody drug conjugates" (320) and "Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases" (198).

Published TypeFieldAccessCitations

Showing 48 of 48 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Jun Y. Axup et al. · Proceedings of the National Academy of Sciences Open access	17 Sep 2012	594
2	A general approach to site-specific antibody drug conjugates Feng Tian et al. · Proceedings of the National Academy of Sciences Open access	17 Jan 2014	320
3	Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases Natsuko Nomura, Sandra Pastorino, Pengfei Jiang et al. · Cancer Cell International Open access	19 Mar 2014	198
4	Optimized clinical performance of growth hormone with an expanded genetic code Ho Cho et al. · Proceedings of the National Academy of Sciences Open access	16 May 2011	198
5	ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers Lillian K. Skidmore, Sukumar Sakamuri, Nick A. Knudsen et al. · Molecular Cancer Therapeutics	15 Jul 2020	166
6	FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents James Mu et al. · Diabetes Open access	31 Dec 2011	161
7	Restoration of leptin responsiveness in diet‐induced obese mice using an optimized leptin analog in combination with exendin‐4 or FGF21 Timo D. Müller, Lorraine M. Sullivan, Kirk M. Habegger et al. · Journal of Peptide Science Open access	4 May 2012	156
8	Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates Jeffrey C. Kern et al. · Journal of the American Chemical Society	9 Jan 2016	147
9	GLP-1/Glucagon Coagonism Restores Leptin Responsiveness in Obese Mice Chronically Maintained on an Obesogenic Diet Christoffer Clemmensen, Joseph R. Chabenne, Brian Finan et al. · Diabetes Open access	31 Dec 2013	136
10	Antibody Conjugates with Unnatural Amino Acids Trevor J. Hallam, Erik D. Wold, Alan F. Wahl et al. · Molecular Pharmaceutics	21 Apr 2015	127
11	In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates Dowdy Jackson et al. · PLoS ONE Open access	14 Jan 2014	122
12	Site-Specific Antibody–Polymer Conjugates for siRNA Delivery Hua Lu, Danling Wang, Stephanie A. Kazane et al. · Journal of the American Chemical Society Open access	7 Aug 2013	109
13	Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs Jeffrey C. Kern, Deborah Dooney, Rena Zhang et al. · Bioconjugate Chemistry	29 Jul 2016	97
14	Molecular aspects of rheumatoid arthritis: role of transcription factors Hiroshi Okamoto, Thomas P. Cujec, Hisashi Yamanaka et al. · FEBS Journal	25 Jul 2008	91
15	Bispecific small molecule–antibody conjugate targeting prostate cancer Chan Hyuk Kim, Jun Y. Axup, Brian R. Lawson et al. · Proceedings of the National Academy of Sciences Open access	14 Oct 2013	85
16	Antibody–drug conjugates: an emerging modality for the treatment of cancer Mauricio Leal, Puja Sapra, Sara A. Hurvitz et al. · Annals of the New York Academy of Sciences	Aug 2014	78
17	A CXCR4‐Targeted Site‐Specific Antibody–Drug Conjugate Sumith A. Kularatne, Vishal A. Deshmukh, Jennifer Ma et al. · Angewandte Chemie International Edition Open access	11 Sep 2014	70
18	YC-1 Induces S Cell Cycle Arrest and Apoptosis by Activating Checkpoint Kinases Eun-Jin Yeo, Jihye Ryu, Yang‐Sook Chun et al. · Cancer Research	15 Jun 2006	65
19	Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells Philip E. Brandish et al. · Bioconjugate Chemistry	20 Jun 2018	59
20	Multiformat T‐Cell‐Engaging Bispecific Antibodies Targeting Human Breast Cancers Yu J Cao, Jun Y. Axup, Jennifer S. Y. Ma et al. · Angewandte Chemie International Edition Open access	27 Apr 2015	51
21	Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma Vivek Subbiah, Sant P. Chawla, Anthony Paul Conley et al. · Clinical Cancer Research Open access	2 Jun 2023	50
22	Recruiting Cytotoxic T Cells to Folate‐Receptor‐Positive Cancer Cells Sumith A. Kularatne, Vishal A. Deshmukh, Marco Gymnopoulos et al. · Angewandte Chemie International Edition Open access	25 Sep 2013	38
23	Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice Raul C. Camacho, Peter Zafian, Joana Achanfuo-Yeboah et al. · European Journal of Pharmacology	3 Jul 2013	38
24	Harnessing the power of an expanded genetic code toward next-generation biopharmaceuticals Mingchao Kang, Yingchun Lu, Sigeng Chen et al. · Current Opinion in Chemical Biology Review	27 Jul 2018	33
25	Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment Prathap Nagaraja Shastri, Jingjing Zhu, Lillian K. Skidmore et al. · Molecular Cancer Therapeutics	4 Jun 2020	29
26	Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management HETING CHEN, Olof Mollstedt, Men-Hwei Tsai et al. · Current Medicinal Chemistry	11 May 2014	27
27	1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) John Paul Shen, Russell Kent Pachynski, Luke T. Nordquist et al. · Annals of Oncology Open access	Oct 2023	23
28	Troubleshooting PEG-hGH detection supporting pharmacokinetic evaluation in growth hormone deficient patients Heather A. Myler, Sami McVay, Jüergen Kratzsch · Journal of Pharmacological and Toxicological Methods	5 Jan 2010	23
29	Summary of Confirmation Cut Point Discussions Holly W. Smith, Michael S. Moxness, Robin Marsden · The AAPS Journal Open access	4 Mar 2011	22
30	Fetal fetuin selectively induces apoptosis in cancer cell lines and shows anti-cancer activity in tumor animal models Chun-Li Yu, Men-Hwei Tsai · Cancer Letters	May 2001	20
31	Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer Lillian K. Skidmore, David M Mills, Ji Young Kim et al. · Molecular Cancer Therapeutics Open access	22 Aug 2024	19
32	Role of tRNA Orthogonality in an Expanded Genetic Code Tsotne Javahishvili, Anthony Manibusan, Shaila Srinagesh et al. · ACS Chemical Biology Open access	20 Jan 2014	19
33	Comparison of bioanalytical methods for the quantitation of PEGylated human insulin Kristine de Dios, Anthony Manibusan, Robin Marsden et al. · Journal of Immunological Methods	6 Aug 2013	17
34	Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase Minghao Sun, Jonathan Ross Hart, Petra Hillmann et al. · Cell Cycle Open access	Nov 2011	13
35	Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study Mark Brantly, Brooks Kuhn, Humam Farah et al. · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation Open access	2024	10
36	Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development Wayne K. Yu, Mysore P. Ramprasad, Manoj Kumar Pal et al. · PLoS ONE Open access	10 Jul 2023	9
37	Single‐stage chromatographic clarification of Chinese Hamster Ovary cell harvest reduces cost of protein production Brian W. O’Mara, Naveen Kumar Singh, Alicia Menendez et al. · Biotechnology Progress Open access	4 Jan 2023	9
38	Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle Sarah E. Attreed, Christina Silva, Monica Rodriguez-Calzada et al. · Frontiers in Microbiology Open access	4 Apr 2024	5
39	1828P ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01) Scott T. Tagawa, Jianzhong Shen, Lillian K. Skidmore et al. · Annals of Oncology Open access	Oct 2023	4
40	Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection Maribel Beaumont et al. · AAPS Open Open access	8 Aug 2018	4
41	41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models Xiaofeng Zhang, D. Mills, Jin‐Ock Kim et al. · Annals of Oncology Open access	Oct 2023	3
42	250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation Jianqin Lu, G. T. Budd, Sophia Frentzas et al. · Annals of Oncology Open access	May 2022	3
43	Site-Specific Antibody-Drug Conjugates Feng Tian, Dowdy Jackson, Yun Bai · Cancer drug discovery and develogment/Cancer drug discovery and development Book chapter	2018	3
44	Conjugates of Heme-Thiolate Enzymes with Photoactive Metal-Diimine Wires Stephen M. Contakes, Yen Nguyen, Harry B. Gray et al. · Structure and bonding Book chapter	2006	3
45	Porcine interferon-alpha but not interferon-lambda inhibits replication of genotypically diverse PRRSV isolates in vitro Samantha J. Hau, Steven G. Kellner, Nickolas Knudsen et al. · Frontiers in Veterinary Science Open access	3 Sep 2026	0
46	71P Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers Lillian K. Skidmore, D. Mills, J.Y. Kim et al. · Annals of Oncology Open access	Oct 2023	0
47	Limitations of employing antibody drug conjugates (ADCs) for targeting HIV infected cells as a strategy for hiv cure Julie Strizki, Donald J. Graham, Meiqing Lu et al. · Journal of Virus Eradication Open access	Dec 2015	0
48	Overview Thomas O. Daniel · Journal of the American Society of Nephrology	Nov 2003	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.